Abstract Disruption of the lung endothelial and epithelial barriers during acute inflammation leads to excessive neutrophil migration. It is likely that activated platelets promote pulmonary recruitment of neutrophils during inflammation, and previous studies have found that anti-platelet therapy and depletion of circulating platelets have lung-protective effects in different models of inflammation. Because ADP signaling is important for platelet activation, I investigated the role of the ADP-receptor P2Y 1 , a G protein-coupled receptor expressed on the surface of circulating platelets, during lipopolysaccharide (LPS)-induced inflammation and lung injury in P2Y 1 -null and wild-type mice. Systemic inflammation was induced by a single intraperitoneal dose of LPS (3 mg/kg), and the mice were analyzed 24 h posttreatment. The data show that the LPS-induced inflammation levels were comparable in the P2Y 1 -null and wild-type mice. Specifically, splenomegaly, counts of circulating platelets and white blood cells (lymphocytes and neutrophils), and assessments of lung injury (tissue architecture and cell infiltration) were similar in the P2Y 1 -null and wild-type mice. Based on my results, I conclude that lung injury during LPS-induced inflammation in mice is independent of P2Y 1 signaling. I propose that if a blockade of purinergic signaling in platelets is a potential lung-protective strategy in the treatment of acute inflammation, then it is more likely to be a result of the disruption of the signaling pathway mediated by P2Y 12 , another G protein-coupled receptor that mediates platelet responses to ADP.
Introduction
Acute lung injury is a condition of acute inflammation that results from a disruption of the lung endothelium and excessive transepithelial neutrophil migration [1] . There is growing evidence that platelets contribute to lung injury during inflammation by promoting pulmonary recruitment of neutrophils [2, 3] . For instance, in a study of sepsis-induced lung injury, mice that were depleted of platelets were found to have significantly lower levels of both neutrophil activation and lung damage [2] .
Platelets, which contribute to hemostasis through their roles in thrombus formation, play important roles in inflammation by interacting with other cells of the immune system and by secreting inflammatory mediators [4] . Upon vessel injury, circulating platelets are activated, which leads to platelet aggregation and platelet secretion of second mediators (such as ADP) that recruit other platelets [5] .
ADP-induced platelet aggregation is mediated by two members of the P2Y receptor family, P2Y 1 and P2Y 12 , both of which are present on the surfaces of platelets [6, 7] . P2Y 1 is a G q -coupled receptor. Stimulation of P2Y 1 causes PLCβ activation and calcium mobilization, resulting in platelet shape change and aggregation [8] . In addition to platelets, P2Y 1 is found in a wide range of cells and tissues, including vascular endothelial cells, leukocytes, and monocytes [9] . Previous studies have shown that P2Y 1 on endothelial cell surfaces modulates leukocyte recruitment into the endothelium, suggesting a role for P2Y 1 in vascular inflammation [10] . Other studies have investigated the role of P2Y 1 in neuroinflammation. For example, in a study of neuroinflammation induced by cerebral stroke, it was found that P2Y 1 -null mice exhibited significantly less altered cognitive decline [11] . In another study, peripheral pretreatment with a selective P2Y 1 antagonist resulted in improved nociception in a model of formalininduced inflammatory pain [12] . However, my colleagues and I have found that a deficiency of P2Y 1 did not influence inflammation levels or lung injury in a murine model of sepsis [13] . The discrepancy between the results of different studies suggests that the role of P2Y 1 in inflammation may depend on the type of inflammation. P2Y 12 is a G i -coupled receptor. Stimulation of P2Y 12 leads to inhibition of adenylyl cyclase and potentiation of platelet secretion. P2Y 12 has been found in platelets [14] , microglia [15] , and other cells of the immune system, including dendritic cells, monocytes, and lymphocytes [16, 17] . P2Y 12 has been shown to play a predominant role in inflammation. Both a deficiency of P2Y 12 and a blockade of the P2Y 12 signaling pathway have been found to reduce inflammation in a variety of models, including myocardial infarction [18] , pancreatitis [19] , and sepsis [2] . For example, pretreatment with the P2Y 12 antagonist clopidogrel was found to result in diminished cell infiltration in the lung in a rat model of lipopolysaccharide (LPS)-induced systemic inflammation [20] .
My colleagues and I have previously shown that a loss of P2Y 1 signaling had no effect on inflammation levels or lung injury in a murine model of sepsis, as no difference was detected when septic P2Y 1 -null mice were compared with the septic wild-type (WT) control [13] . However, these observations could be specific to sepsis and sepsis-induced lung injury. No studies have yet analyzed the role of P2Y 1 in LPSinduced inflammation and lung injury. Hence, I investigated the level of lung injury in P2Y 1 -null mice in which inflammation was induced by a single intraperitoneal (i.p.) dose of LPS (3 mg/kg; 24-h time point). My findings revealed for the first time that P2Y 1 deficiency does not alter the level of LPSinduced inflammation, which I evaluated in terms of circulating white blood cells or acute lung injury. My results indicate that lung injury during LPS-induced inflammation occurs independently of P2Y 1 signaling.
Material and methods

Materials
All reagents were analytical grade and obtained from Thermo Fisher Scientific (Waltham, MA), unless stated otherwise. Lipopolysaccharides from Salmonella enterica serotype Enteritidis (L7770; protein content ≤1%) and bovine serum albumin (BSA) were obtained from Sigma-Aldrich (St. Louis, MO). Hank's balanced salt solution (HBSS) and PBS were purchased from Mediatech, Inc. (Manassas, VA).
Animals and treatments
All procedures for the care and handling of the animals adhered to the National Institutes of Health standards and were approved by the Institutional Animal Care and Use Committee at Temple University School of Medicine (Philadelphia, PA). The age-matched, pathogen-free C57BL/ 6 male mice (weight 25-30 g) used in this study were selected from either a wild-type strain or a P2Y 1 -null strain that was generated by subcontract with Lexicon Genetics Inc. (Woodlands, TX) using knockout constructs as previously described [21, 22] . The mice were housed in a climatecontrolled facility and given free access to food and water.
Wild-type and P2Y 1 -null mice were treated with a single intraperitoneal dose of LPS (3 mg/kg) dissolved in a saline solution. Control mice received the saline solution only (vehicle). The specific LPS dose was chosen on the basis of previous studies that were carried out in our laboratory [23] and by other groups [24, 25] .
At 24-h post-LPS treatment, mice were anesthetized and blood samples were collected by cardiac puncture (10:1 ratio of blood in 3.8% sodium citrate) for hematology studies that were performed using the Hemavet® Multispecies Hematology System (Drew Scientific Inc., Oxford, CT). The mice were euthanized by cardiac puncture and exsanguination. Lungs and spleens were weighed and the results are presented as organ weight (milligrams) per body weight (grams), as previously described [23, [26] [27] [28] .
Lung histopathology
Lung sections were embedded in paraffin, cut into 5-μm sections, and stained with hematoxylin and eosin (H&E). Morphological analysis of random fields (n = 6) from each section (n = 3 sections/animal) was performed by a second independent and blinded observer using previously described methods [29] . Acute lung injury (ALI) was scored on the basis of four parameters: (a) alveolar capillary congestion, (b) hemorrhage, (c) infiltration or aggregation of neutrophils in the airspace or the vessel wall, and (d) thickness of the alveolar wall. Each parameter was graded from 0 to 4 based on the damage present as follows: 0 indicates no or little damage, 1 indicates less than 25% damage, 2 indicates 25-50% damage, 3 indicates 50-75% damage, and 4 indicates more than 75% damage. The overall degree of ALI was determined by adding the scores of all four parameters.
Myeloperoxidase peroxidation
Lungs were homogenized and sonicated in cold PBS (pH 7.4). After centrifugation at 10,000 × g for 10 min at 4°C, myeloperoxidase peroxidation (MPO) levels were detected using an MPO assay kit (Cayman, USA).
Statistical analysis
Differences among the groups were analyzed using a one-way ANOVA statistical test. Bonferroni's Multiple Comparison Test was used for posttest analyses. p < 0.05 was considered to be significant. Data are reported as mean ± standard error of the mean (SEM) for each group.
Results and discussion
To investigate the role of P2Y 1 in lung injury that occurs during LPS-induced inflammation, I treated WT and P2Y 1 -null mice with either a single i.p. dose of LPS (3 mg/kg) or of the vehicle only (PBS), and samples were collected 24 h after treatment. All of the mice used in the experiment survived for 24 h following the LPS treatment. The changes in body weight for the groups included in the study are shown in Table 1 . My results indicate that the LPS treatment resulted in a significant decrease in the body weight of the mice in the study (p < 0.05; LPS-treated vs. vehicle-treated), with no difference between WT and P2Y 1 -null mice.
Next, I looked for possible changes in splenomegaly 24 h after the LPS treatment (i.p. dose of 3 mg/kg of LPS) (Fig. 1) . The data are expressed as milligrams (mg) of organ weight per gram of animal weight. When I compared the results across the different treatment groups, I found that the LPS treatment resulted in a 1.5-fold increase in the average spleen weight of the WT mice (p < 0.05; LPS-treated WT vs. vehicle-treated WT) and a 1.75-fold increase in the average spleen weight of the P2Y 1 -null mice (p < 0.05; LPS-treated P2Y 1 -null mice vs. vehicle-treated P2Y 1 -null mice, Fig. 1) . Interestingly, the average spleen weight of the vehicle-treated P2Y 1 -null mice was significantly lower than that of their WT counterparts (p < 0.05; vehicle-treated WT vs. vehicle-treated P2Y 1 -null), suggesting that P2Y 1 plays an important role in spleen development. Previous studies have shown that P2Y 1 is expressed on rat splenic sinus endothelial cells [30] , but specific roles for P2Y 1 in the development and function of the spleen have not yet been described.
The splenomegaly most likely results primarily from an increase in the immune cell count, which has been shown to occur in the course of inflammation [28] . Hence, I examined the number of circulating white blood cells (Fig. 2a) . White blood cells were elevated in both the WT and P2Y 1 -null mice that were treated with LPS (p < 0.05). Based on an analysis of cell populations, I noted that neutrophils were increased in both LPStreatment groups compared with the vehicle-treated control groups (p < 0.05), and I observed no significant difference between the LPS-treated P2Y 1 -null mice and the LPS-treated WT mice (Fig. 2b) . Indeed, the lymphocyte count was significantly decreased in both LPS-treated WT and P2Y 1 -null mice (Fig. 2c , p < 0.05) compared with that in their respective vehicle-treated controls. However, the decrease was more significant in LPStreated WT mice than in LPS-treated P2Y 1 -null mice (Fig. 2c , p < 0.05). Interestingly, P2Y 1 seems to be expressed in lymphocytes [9] but not in neutrophils [9] . It is possible that P2Y 1 deficiency prevents leukocyte release from the bone marrow or results in a decrease in the migration of lymphocytes into tissues. I found no significant difference when platelet counts were compared across all treatment groups (Fig. 2d) .
To assess the functional consequence of the observed increase in the parameters of inflammation, I investigated whether P2Y 1 deficiency alters LPS-induced ALI (n = 5; Fig. 3 ). I found that mice treated with LPS (a single i.p. dose of 3 mg/kg of LPS; 24-h time point) exhibited an increase in lung weight (p < 0.05; LPS- treated groups vs. untreated groups), with similar results in both the WT and P2Y 1 -null backgrounds (Fig. 3a) . I analyzed representative images of lung sections (H&E staining; Fig. 3b ) and found that lung architecture was compromised in LPS-treated mice but not in the vehicle-treated mice. We found similar results in both the P2Y 1 -null and WT backgrounds (p < 0.05; LPStreated groups vs. untreated groups). Likewise, histology scores (Fig. 3c) based on alveolar capillary congestion, hemorrhage, infiltration or aggregation of neutrophils in the airspace or the vessel wall, and thickness of the alveolar wall were significantly higher in the LPStreated WT and P2Y 1 -null groups compared with those in their respective vehicle-treated groups (p < 0.05; LPS-treated groups vs. untreated groups). Again, I observed no difference in the lung injury between WT and P 2 Y 1 -n u l l m i c e i n r e s p o n s e t o L P S e x p o s u r e . Neutrophil infiltration was analyzed using MPO measurements, as shown in Fig. 3d . These data are consistent with the H&E findings in which neutrophil infiltration was higher in both the LPS-treated P2Y 1 -null and WT mice than in either of the vehicle-treated P2Y 1 -null or WT mice (p < 0.05; LPS-treated groups vs. untreated groups). My results are consistent with previous findings in which sepsis-induced lung injury was not altered in P2Y 1 -null mice compared with that in the septic WT group [13] . Interestingly, P2Y 1 seems not to be expressed in the lung [31] or on neutrophils [9] , which could explain why lung injury is not affected by a loss of P2Y 1 signaling. In contrast with my findings, P2Y 1 deficiency was protective in a model of neuroinflammation induced by cerebral stroke [11] and in a model of formalin-induced inflammatory pain [12] . Moreover, P2Y 1 on endothelial cell surfaces modulates leukocyte recruitment during vascular inflammation [10] . As P2Y 1 seems to be selectively expressed in certain immune cells (such as lymphocytes, monocytes, and platelets [9] ) but not in others (such as neutrophils [9] ), the differences in outcomes may be related to the immune cells mediating the biological/pathological phenomena observed while using a specific model. Activation of P2Y 1 , a G q -coupled receptor, causes calcium mobilization and activation of PLCβ [1] . PLCβ is a key regulator of cell functions [32] and seems to be activated during inflammation in leukocytes [33] and endothelial cells [34] . Hence, it is possible that the protective effects associated with a P2Y 1 deficiency that have been observed in other models of inflammation resulted from decreased PLCβ activity. In contrast, activation of PLCβ may not be a determinant for LPS-induced lung injury, especially considering that P2Y 1 seems not to be expressed in the lung [5] . In platelets, P2Y 1 signaling leads to platelet shape changes and calcium mobilization [1] , whereas P2Y 12 signaling leads to inhibition of adenylyl cyclase and potentiation of platelet secretion of signaling molecules, including inflammatory mediators. As a result, P2Y 12 deficiency is expected to result in decreased platelet secretion of inflammatory mediators, which would likely lead to reduced lung injury during inflammation. In contrast, P2Y 1 signaling in platelets does not potentiate secretion, which might explain why P2Y 1 deficiency offers no protection against lung injury during LPS-induced inflammation.
Conclusions
LPS-induced inflammation and lung injury were not altered by the loss of P2Y 1 signaling, which is consistent with what has been previously observed in sepsis-induced lung injury. These data suggest that lung injury is independent of the receptor P2Y 1 that the role of P2Y 1 during inflammation may depend on the type of inflammation.
